<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00558337</url>
  </required_header>
  <id_info>
    <org_study_id>OS353-CTP 01</org_study_id>
    <nct_id>NCT00558337</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease</brief_title>
  <official_title>An Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Relationship Study of L-Dopa/Carbidopa in a Novel Release Formulation in Parkinson's Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osmotica Pharmaceutical US LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osmotica Pharmaceutical US LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine if a novel levodopa/carbidopa formulation results in a better clinical response on&#xD;
      Parkinson's Disease patients compared to the reference formulation of levodopa/carbidopa in&#xD;
      terms of motor complications, onset of action and response duration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective is to demonstrate a better clinical response profile of novel&#xD;
      levodopa/carbidopa formulation vs. the reference formulation of levodopa/carbidopa in&#xD;
      patients with Parkinson's Disease as judged by motor performance and to describe&#xD;
      pharmacokinetic profile for the novel formulation compared to the reference.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of a novel levodopa/carbidopa formulation providing a better clinical profile than reference levodopa/carbidopa formulation using Unified Parkinson's Disease Rating Scale (UPDRS III) and patient's diary cards</measure>
    <time_frame>every half hour for the first 8 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other measurements to be used for demonstrating clinical profile is UPDRS II and IV, Clinical Global Impression Scale (CGI)/Patient's Global Improvement Scale (PGI), and the Abnormal Involuntary Movement Scale (AIMS)</measure>
    <time_frame>over the course of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levodopa-carbidopa</intervention_name>
    <description>novel levodopa/carbidopa formulation or a reference levodopa/carbidopa formulation</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnostic of Parkinson's Disease, with a Hoehn and Yahr Staging within 2-4,&#xD;
             and L-Dopa therapy complications&#xD;
&#xD;
          -  at least 2years of L-Dopa therapy&#xD;
&#xD;
          -  Patients with the ability to differentiate between &quot;ON&quot; and &quot;OFF&quot; periods&#xD;
&#xD;
          -  Patients who have been receiving stable doses of L-Dopa between 600 and 1600 mg/day,&#xD;
             for at least 2 months prior to the screening visit using a dosing regimen not higher&#xD;
             that 5 times a day, and not expected in the investigator's opinion to need any dose&#xD;
             modifications over the duration of the study&#xD;
&#xD;
          -  Patients presenting a score of at least 2 in the UPDRS IVa, item 32 and/or a score of&#xD;
             at least 2 in the UPDRS IVb, item 39, at screening and randomization visits based on&#xD;
             clinical records for the first visit and daily diary cards at randomization time.&#xD;
&#xD;
          -  Willing and able to understand and sign Informed Consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of any known secondary Parkinsonian syndrome, (vascular,&#xD;
             toxin or drug-induced, metabolic or infectious, etc) or other neurodegenerative&#xD;
             disorder with parkinsonism (Progressive Supranuclear Palsy, Corticobasal Degeneration,&#xD;
             Multiple System Atrophy, etc).&#xD;
&#xD;
          -  Patients receiving other concomitant anti-Parkinsonian pharmacological therapies&#xD;
             affecting L-dopa or dopamine metabolisom (COMT inhibitors or MAO inhibitors)&#xD;
&#xD;
          -  Subjects who have undergone prior functional neurosurgical treatment for PD (ablation&#xD;
             or Deep Brain Stimulation).&#xD;
&#xD;
          -  Patient with a L-dopa dosage regimen greater than 5 times a day which is not able to&#xD;
             be adapted to a q.i.d. regimen.&#xD;
&#xD;
          -  Patients having received L-dopa / Decarboxylase inhibitors therapy for less than 2&#xD;
             years.&#xD;
&#xD;
          -  Patients needing nightly doses of L-dopa / Decarboxylase inhibitors apart from the&#xD;
             four daily doses.&#xD;
&#xD;
          -  Any medical condition or past medical history that, in the investigator's judgment,&#xD;
             would increase the risk of exposure to L-dopa / Carbidopa or interfere with the&#xD;
             evaluation of the study objectives.&#xD;
&#xD;
          -  Patients with unstable or clinically significant known medical illness; such as&#xD;
             cardiac, pulmonary, kidney, hepatic and/or gastrointestinal disease that would, in the&#xD;
             investigator's judgment, interfere with the safe course of the study.&#xD;
&#xD;
          -  Cognitive impaired patients, as determined by a score of lesser than 26 on the&#xD;
             Mini-Mental Score Status Examination. (MMSE &lt; 26).&#xD;
&#xD;
          -  Alcohol or illegal drugs abuse.&#xD;
&#xD;
          -  Pregnant or lactating patients.&#xD;
&#xD;
          -  Hypersensitivity to any of the investigational drugs, based on known allergies to&#xD;
             drugs of the same class.&#xD;
&#xD;
          -  Patients having taken any research drugs over the last 30 days prior to the beginning&#xD;
             of the study.&#xD;
&#xD;
          -  Blood donation, or blood products, or participation to a clinical trial with serial&#xD;
             blood withdrawals, within twelve weeks prior to the start of the trial, or intention&#xD;
             to donate blood or blood products within three months following the study completion.&#xD;
&#xD;
          -  Patients who have received some of the following medications with an anticipation of&#xD;
             no more than 7 treatment-drug elimination half-lives of entry time: Dopamine D2&#xD;
             receptor antagonists , isoniazid, anti-epileptic drugs, IMAO A or B, pyridoxine,&#xD;
             ferrous salts or methyldopa.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustavo Fischbein, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Osmotica Pharmaceutical Argentina S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundacion Alfredo Thomson</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Posadas</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramos Mejía</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sirio Libanés</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Frenopático</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>nstituto INEBA</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlínica Bancaria</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Rosarina de Neuro-Rehabilitación</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Bernardo</name>
      <address>
        <city>Salta</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>November 12, 2007</study_first_submitted>
  <study_first_submitted_qc>November 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2007</study_first_posted>
  <last_update_submitted>January 13, 2009</last_update_submitted>
  <last_update_submitted_qc>January 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>Gustavo Fischbein</name_title>
    <organization>Osmotica Pharmaceutical Argentina</organization>
  </responsible_party>
  <keyword>Treatment of Parkinson's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

